Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

Radhakrishnan Ramchandren,Eva Domingo-Domenech,Antonio Rueda,Marek Trneny,Tatyana Feldman,H Lee,Mariano Provencio,Christian Sillaber,Jonathon B. Cohen,Kerry J. Savage,Wolfgang Willenbacher,Azra H. Ligon,Jing Ouyang,Robert A. Redd,Scott J. Rodig,Margaret A. Shipp,Mariana Sacchi,Anne Sumbul,Philippe Armand,Stephen M. Ansell

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

2019

PURPOSENivolumab, an anti–programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohor...

Keywords:

Refractory
Monoclonal antibody
Lymphoma
Pathology
Nivolumab
Oncology
Internal medicine
Medicine
Checkmate
newly diagnosed
Young adult
Extramural
Clinical trial
advanced stage
hodgkin lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations